Pembrolizumab (Immunotherapy)
Treatment for Breast Cancer
Typical Dosage: 200 mg every 3 weeks or 400 mg every 6 weeks
Effectiveness
55%
Safety Score
40%
Clinical Trials
72
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
200 mg every 3 weeks or 400 mg every 6 weeks
Time to Effect
Weeks to months
Treatment Duration
Up to 2 years or until disease progression/unacceptable toxicity
Evidence Quality
MODERATENumber Needed to Harm (NNH)
10(Treat 10 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$180,000
Monitoring:$6,000
Side Effect Mgmt:$4,000
Total Annual:$190,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$400,000/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$633,333
Cost per Remission
$1,900,000
Comparison vs Chemotherapy alone
Cost Difference
+$160,000/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Pembrolizumab (Immunotherapy) Outcomes
for Breast Cancer
Efficacy Outcomes
Overall Effectiveness
+55%
Response Rate
+30%
Remission Rate
+10%
Common Side Effects
Fatigue
+30%
Nausea
+20%
Diarrhea
+15%
Pruritus
+20%
Immune-related adverse events (colitis, hepatitis, pneumonitis, endocrinopathies)
+15%
Sources:
Active Clinical Trials
17 active trials recruiting for Pembrolizumab (Immunotherapy) in Breast Cancer
Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer
NCT07188246NOT YET RECRUITINGPHASE2
40 participants
INTERVENTIONAL
London, Canada +1 more
Started: Oct 1, 2025
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
NCT04373031ACTIVE NOT RECRUITINGPHASE2
12 participants
INTERVENTIONAL
Portland, United States
Started: Dec 30, 2020
Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer
NCT03971045RECRUITINGPHASE2
46 participants
INTERVENTIONAL
Milan, Italy
Started: May 20, 2020
Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer
NCT06472583RECRUITINGPHASE2
78 participants
INTERVENTIONAL
Gliwice, Poland
Started: Apr 11, 2024
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]
NCT03747120ACTIVE NOT RECRUITINGPHASE2
138 participants
INTERVENTIONAL
Los Angeles, United States +4 more
Started: Jan 25, 2019
ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
NCT07015853NOT YET RECRUITINGPHASE2
34 participants
INTERVENTIONAL
Los Angeles, United States
Started: Sep 1, 2025
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
NCT03025035ACTIVE NOT RECRUITINGPHASE2
14 participants
INTERVENTIONAL
Los Angeles, United States
Started: Sep 10, 2017
A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer
NCT03632941ACTIVE NOT RECRUITINGPHASE2
8 participants
INTERVENTIONAL
Durham, United States
Started: Mar 1, 2019
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
NCT05973864RECRUITINGPHASE2
220 participants
INTERVENTIONAL
Amiens, France +19 more
Started: Mar 11, 2025
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
NCT05491226ACTIVE NOT RECRUITINGPHASE2
35 participants
INTERVENTIONAL
Los Angeles, United States
Started: Nov 17, 2023
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
NCT03362060ACTIVE NOT RECRUITINGPHASE1
20 participants
INTERVENTIONAL
Boston, United States +2 more
Started: Dec 12, 2017
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
NCT06532812RECRUITINGPHASE1, PHASE2
85 participants
INTERVENTIONAL
Beijing, China
Started: Aug 22, 2024
Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy
NCT06880029RECRUITINGPHASE1, PHASE2
20 participants
INTERVENTIONAL
Vila Nova de Gaia, Portugal
Started: Sep 1, 2024
Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer
NCT06407310NOT YET RECRUITINGPHASE2
25 participants
INTERVENTIONAL
Started: Jul 1, 2024
Breast Cancer Study of Preoperative Pembrolizumab + Radiation
NCT03366844ACTIVE NOT RECRUITINGPHASE1, PHASE2
66 participants
INTERVENTIONAL
Los Angeles, United States
Started: Dec 22, 2017
A Phase II Open-label Study of Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
NCT06353997RECRUITINGPHASE2
12 participants
INTERVENTIONAL
Los Angeles, United States +3 more
Started: Sep 5, 2024
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929ACTIVE NOT RECRUITINGPHASE1
126 participants
INTERVENTIONAL
Boston, United States +18 more
Started: Oct 26, 2022
Showing 20 of 73 total trials